The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

PAREXEL International Corp

Nasdaq: PRXL
Last

(U.S.) $66.91

Today's change-0.58 -0.86%
Updated August 31 11:02 AM EDT. Delayed by at least 15 minutes.
 

PAREXEL International Corp

Nasdaq: PRXL
Last

(U.S.) $66.91

Today's change-0.58 -0.86%
Updated August 31 11:02 AM EDT. Delayed by at least 15 minutes.

PAREXEL International Corp crosses below 125-day moving average

PAREXEL International Corp is lower today, dropping (U.S.)$0.58 or 0.86% to (U.S.)$66.91 and crossing below its 125-day moving average. Shares have lost 0.95% over the last five days, but have gained 20.43% over the last year to date. This security has outperformed the S&P 500 by 20.09% during the last year.

Key company metrics

  • Open(U.S.) $67.00
  • Previous close(U.S.) $67.49
  • High(U.S.) $67.61
  • Low(U.S.) $66.51
  • Bid / Ask(U.S.) $66.82 / (U.S.) $66.91
  • YTD % change+20.43%
  • Volume175,366
  • Average volume (10-day)932,045
  • Average volume (1-month)879,938
  • Average volume (3-month)729,205
  • 52-week range(U.S.) $52.19 to (U.S.) $76.17
  • Beta1.21
  • Trailing P/E25.27×
  • P/E 1 year forward21.08×
  • Forward PEG1.23×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.65
Updated August 31 11:02 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.34%

Based on its net profit margin of 6.34%, PAREXEL International Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.28%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue605576575574
Total other revenue--------
Total revenue605576575574
Gross profit167170175174
Total cost of revenue438406400400
Total operating expense566522522520
Selling / general / administrative81889999
Research & development--------
Depreciation / amortization23212020
Interest expense (income), net operating--------
Unusual expense (income)20------
Other operating expenses, total--------
Operating income39545354
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax37545455
Income after tax34383937
Income tax, total3161518
Net income34383937
Total adjustments to net income--------
Net income before extra. items34383937
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items34383937
Inc. avail. to common incl. extra. items34383937
Diluted net income34383937
Dilution adjustment--0----
Diluted weighted average shares56565656
Diluted EPS excluding extraordinary itemsvalue per share0.610.680.700.67
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.930.680.700.67